Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma

International Journal of Pancreatology

Volumn 21, Issue 2, 1997, Pages 127-143

  Dergham, Sanaa T ^a   Dugan, Michael C ^a   Kucway, Roger ^a   Du, Wei ^a   Kamarauskiene, Dalia S ^a   Vaitkevicius, Vainutis K ^a   Crissman, John D ^a   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenocarcinoma; Chemotherapy; Grade; K ras; p53; Pancreas; Radiation; Stage; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; DNA PRIMERS; FEMALE; GENE EXPRESSION; GENES, P53; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030999374     PISSN: 01694197     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Fialkow PJ. The origin and development of human tumors studied with cell markers. N Engl J Med 1974; 291: 26-35.
2. Caldas C, Kern SE. K-ras mutation and pancreatic adenocarcinoma. Int J Pancreatol 1995; 18: 1-6.
3. Kalthoff H, Schmiegel W, Roeder C, Kasche D, Schmidt A, Lauer G, Thiele H-G, Honold G, Pantel K, Riethmueller G, Scherer E, Maurer J, Maacke H, Deppert W. p53 and K-ras alterations in pancreatic epithelial cell lesions. Oncogene 1993; 8: 289-298.
4. Es JM, Polak MM, van den Berg FM, Ramsoekh TB, Craanen ME, Hruban RH, Offerhaus GJA. Molecular markers for diagnostic cytology of neoplasm in the head region of the pancreas: mutation of K-ras and over-expression of the p53 protein product. J Clin Pathol 1995; 48: 218-222.
5. Pellegata NS, Sessa F, Renault B, Bonato M, Leone BE, Solcia E, Ranzani GN. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 1994; 54: 1556-1560.
6. Berrozpe G, Schaeffer J, Peinado MA, Real FX, Perucho M. Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer, Int J Cancer 1994; 58: 185-191.
7. Parker SL, Tong T, Bolden S, Wingo P. Cancer statistics 1996. CA Cancer J Clin 1996; 65: 5-27.
8. Hollstein M, Sidransky D, Vogelstein B, Harfis CC. p-53 mutations in human cancers. Science 1991; 253: 49-53.
9. Hermreck AS, Thomas CY IV, Friesen SR. Importance of pathologic staging in the surgical management of adenocarcinoma of the pancreas. Am J Surg 1974; 127: 653-657.
10. Sarkar FH, Valdivieso M, Borders J, Yao K-L, Raval M, Madan S, Sreepathi P, Shimoyama R, Steiger Z, Visscher D, and Crissman J. A universal method for the mutational analysis of K-ras and p53 gene in non-small-cell lung cancer using formalin-fixed paraffin- embedded tissue. Diag Mol Pathol 1995; 4: 266-273.
11. Bos JL. The ras gene family and human carcinigenesis. Mutat Res 1988; 195: 255-271.
12. Caldas C, Kern SE. K-ras mutation and pancreatic adenocarcinoma. Int J Pancreatol 1995; 18: 1-6.
13. Grimmond SM, Raghanam D, Russell PJ. Detection of a rare point mutation in Ki-ras of a human bladder cancer xenograft by polymerase chain reaction and direct sequencing. Urolog Res 1992; 20: 121-126.
14. Jacoby RF, Llor X, Teng BB, Davidson NO, Brasitus TA. Mutations in the K-ras oncogene induced by 1,2-dimethyl-hydazine in preneoplastic and neoplastic rat colonic mucosa. J Clin Invest 1991; 87: 624-630.
15. Visscher DW, Sarkar FH, Shimoyama RK, et al. Correlation between p53 immunostaining patterns and gene sequence mutations in breast carcinoma. Diag Mol Pathol 1996; 5: 187-193.
16. Nakamori S, Yashima K, Murakami Y, Ishikawa O, Ohigashi H, Imaoka S, Yaegashi S, Konishi Y, Sekiya T. Association of p53 gene mutations with short survival in pancreatic adenocarcinoma. J Cancer Res 1995; 86: 174-181.
17. Yokoyama M, Yamanaka Y, Freiss H, Buchler M, Korc M. p53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness. Anticancer Res 1994; 14: 2477-2484.
18. Boschman C, Reddy JK, Rao MS. Immunohistochemical analysis of p53 protein expression in human pancreatic ductal adenocarcinomas and precursor lesions. Lab Invest 1994; 70: 129A.
19. Hameed M, Marrero AM, Conlon KC, Brennen MF, Klimstra D. Expression of p53 nucleophosphoprotein in in situ pancreatic ductal adenocarcinoma: an immunohistochemical analysis of 100 cases. Lab Invest 1994; 70: 132A.
20. Zhang SY, Ruggeri B, Agarwal P, Sorting AF, Obara T, Ura H, Namiki M, Klein-Szanto JP. Immunohistochemical analysis of p53 expression in human pancreatic carcinomas. Arch Pathol Lab Med 1994; 118: 150-154.
21. Yanagisawa A, Ohtake K, Ohashi K, Hori M, Kitagawa T, Sugano H, Kato Y. Frequent cKi-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflamation. Cancer Res 1993; 53: 953-956.
22. Lemoine NR, Jain S, Hughes CM, Staddon SL, Maillet B, Hall PA, Kloppel G. Ki-ras oncogene activation in preinvasive pancreatic cancer. Gastroenterology 1992; 102: 230-236.
23. vanKranen HJ, Vermoulen E, Schoren L, Bax J, Woutersen RA, vanLersel P, van Kreiji CF, Scherer E. Activation of c-K-ras is frequent in pancreatic carcinomas of Syrian hamsters, but is absent in pancreatic tumors of rats. Carcinogenesis 1991; 12: 1477-1482.
24. Cermu WL, Mangold KA, Scarpelli DG. K-ras mutation is an early event in pancreatic duct carcinogenesis in the Syrian golden hamster. Cancer Res 1992; 52: 4507-4513.
25. Motojima K, Urano T, Nagata Y, Shiku H, Tsunoda T, Kanematsu T. Mutations in the Kirsten-ras oncogene are common but lack correlation with prognosis and rumor stage in human pancreatic carcinoma. Am J Gastroenterol 1991; 86: 1784-1788.
26. Chen YQ, Gao X, Grignon DJ, Sarkar FH, Sakr WA, Cipfiano SC, Honn KV, Borders J, Crissman JD. Multiple mechanisms of p53 inactivation in prostatic carcinoma. Cancer Mol Biol 1994; 1: 357-367.
27. Redston MS, Caldas C, Seymour AB, Hruban RH, de Costa L, Yeo CJ, Kern SE. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994; 54: 3025-3033.
28. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutation in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-4878.
29. Vans ES MJ, Polak MM, van den Berg FM, Ramsoekh TB, Craanen ME, Hruban RH, Offerhaus GJA. Molecular markers for diagnostic cytology of neoplasms in the head region of the pancreas: mutation of K-ras and over-expression of the p53 protein product. J Clin Pathol 1995; 48: 218-222.
30. Kasid U, Suy S, Dent P, Ray S, Whiteside TL, Sturgill TW. Activation of Raf by ionizing radiation. Nature 1996; 382: 813-816.